BioSpace

Roche cuts muscle-sparing obesity drug after mid-stage disappointment

Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.

Por BioSpace

1 minuto de lectura
Compartir
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche cuts muscle-sparing obesity drug after mid-stage disappointment

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas